Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions.
Brain
Catecholamine
Dopamine
Norepinephrine
Vesicular monoamine transporter
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
14
11
2022
revised:
28
09
2023
accepted:
10
11
2023
medline:
30
11
2023
pubmed:
30
11
2023
entrez:
30
11
2023
Statut:
epublish
Résumé
Vesicular monoamine transporters (VMATs) are key regulators of neurotransmitter release responsible for controlling numerous physiological, cognitive, emotional, and behavioral functions. They represent important therapeutic targets for numerous pathological conditions. There are two isoforms of VMAT transporter proteins that function as secondary active transporters into the vesicle for storage and release via exocytosis: VMAT1 (SLC18A1) and VMAT2 (SLC18A2) which differ in their function, quantity, and regional expression. VMAT2 has gained considerable interest as a therapeutic target and diagnostic marker. Inhibitors of VMAT2 have been used as an effective therapy for a range of pathological conditions. Additionally, the functionality and phenotypic classification of classical and nonclassical catecholaminergic neurons are identified by the presence of VMAT2 in catecholaminergic neurons. Dysregulation of VMAT2 is also implicated in many neuropsychiatric diseases. Despite the complex role of VMAT2, many aspects of its function remain unclear. Therefore, our aim is to expand our knowledge of the role of VMAT with a special focus on VMAT2 in different systems and cellular pathways which may potentially facilitate development of novel, more specific therapeutic targets. The current review provides a summary demonstrating the mechanism of action of VMAT, its functional role, and its contribution to disease progression and utilization as therapeutic targets.
Identifiants
pubmed: 38034713
doi: 10.1016/j.heliyon.2023.e22413
pii: S2405-8440(23)09621-4
pmc: PMC10687066
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e22413Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Physiol. 1996 Jan 1;490 ( Pt 1):249-56
pubmed: 8745292
J Pharmacol Exp Ther. 1999 Feb;288(2):834-7
pubmed: 9918596
Nucl Med Biol. 2010 Jan;37(1):3-8
pubmed: 20122661
Int J Mol Sci. 2019 May 17;20(10):
pubmed: 31108898
Med Res Rev. 2011 Jul;31(4):483-519
pubmed: 20135628
Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):7-14
pubmed: 9387858
J Psychiatry Neurosci. 2016 Apr;41(3):169-81
pubmed: 26505143
Curr Neuropharmacol. 2016;14(7):665-73
pubmed: 27640517
Annu Rev Pharmacol Toxicol. 2007;47:401-41
pubmed: 17067279
Nat Commun. 2016 Feb 16;7:10652
pubmed: 26879809
Pancreas. 2011 Aug;40(6):883-95
pubmed: 21705949
Pharmacol Ther. 2020 Aug;212:107580
pubmed: 32454050
Am J Med. 2019 Jul;132(7):802-807
pubmed: 30890425
Pharmacol Rev. 2015 Oct;67(4):1005-24
pubmed: 26408528
J Pathol. 2001 Nov;195(4):463-72
pubmed: 11745679
CNS Neurosci Ther. 2015 Aug;21(8):662-71
pubmed: 26122704
PLoS One. 2022 Jan 5;17(1):e0259753
pubmed: 34986152
Biochem Biophys Res Commun. 2016 Feb 19;470(4):792-7
pubmed: 26801555
Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):188-199
pubmed: 30567483
Front Behav Neurosci. 2020 Nov 09;14:578443
pubmed: 33240055
J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1317-1323
pubmed: 31296586
J Neurosci. 1998 Jun 1;18(11):4106-18
pubmed: 9592091
Eur Neuropsychopharmacol. 2002 Jun;12(3):261-8
pubmed: 12007678
J Neurosci. 2007 Sep 26;27(39):10520-9
pubmed: 17898223
Gastroenterology. 2014 Mar;146(3):754-764.e3
pubmed: 24316261
Neuropsychopharmacology. 2006 Dec;31(12):2739-47
pubmed: 16936705
Eur J Pharmacol. 1967 Dec;2(3):236-8
pubmed: 5590350
Biochem J. 2008 Jun 1;412(2):191-209
pubmed: 18466116
J Neurogenet. 2016 Mar;30(1):5-15
pubmed: 27276191
Pharmacol Rev. 2020 Jan;72(1):253-319
pubmed: 31852803
Brain Res. 2002 Oct 25;953(1-2):189-94
pubmed: 12384252
Adv Pharmacol. 2014;69:71-106
pubmed: 24484975
Eur J Pharmacol. 2004 Nov 3;504(1-2):27-32
pubmed: 15507217
Clin Auton Res. 2010 Dec;20(6):331-52
pubmed: 20623313
J Cell Biol. 2001 Mar 19;152(6):1159-68
pubmed: 11257117
Neurol Ther. 2022 Mar;11(1):435-448
pubmed: 34905160
Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):659-78
pubmed: 16741673
ACS Chem Neurosci. 2021 Dec 15;12(24):4580-4586
pubmed: 34813272
P T. 2008 Dec;33(12):690-4
pubmed: 19750050
Proc Natl Acad Sci U S A. 1996 May 14;93(10):5166-71
pubmed: 8643547
Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9977-82
pubmed: 24979780
Integr Med (Encinitas). 2015 Jun;14(3):40-6
pubmed: 26770146
Health Psychol Res. 2022 Jun 28;10(3):36040
pubmed: 35774908
Biochem Biophys Res Commun. 1990 May 31;169(1):123-8
pubmed: 2350337
J Clin Psychopharmacol. 2019 Nov/Dec;39(6):620-627
pubmed: 31688452
Neuropsychopharmacology. 2000 Dec;23(6):667-75
pubmed: 11063922
Am J Psychiatry. 2017 May 1;174(5):476-484
pubmed: 28320223
Neuropharmacology. 2018 Aug;138:282-291
pubmed: 29908239
Front Endocrinol (Lausanne). 2014 May 13;5:73
pubmed: 24860550
J Pharmacol Exp Ther. 2003 Mar;304(3):1181-7
pubmed: 12604695
Mol Neurobiol. 2009 Apr;39(2):149-70
pubmed: 19259829
Curr Top Membr. 2014;73:149-74
pubmed: 24745982
Mol Psychiatry. 2023 Feb;28(2):722-732
pubmed: 36352123
ACS Chem Neurosci. 2015 May 20;6(5):790-9
pubmed: 25746685
Acta Physiol (Oxf). 2022 Jan;234(1):e13725
pubmed: 34403568
Mol Neurobiol. 2014 Dec;50(3):765-96
pubmed: 24878765
J Biol Chem. 2001 Jul 20;276(29):27304-15
pubmed: 11375404
Eur J Pharmacol. 2004 May 25;492(2-3):143-7
pubmed: 15178358
Neuropsychiatr Dis Treat. 2019 Apr 04;15:785-794
pubmed: 31040678
Digestion. 1999 Sep-Oct;60(5):428-39
pubmed: 10473967
Clin Pharmacol Ther. 2016 Nov;100(5):489-499
pubmed: 27506881
J Biol Chem. 1981 Jul 10;256(13):6541-3
pubmed: 7240227
Q J Nucl Med Mol Imaging. 2021 Dec;65(4):396-401
pubmed: 35133098
Parkinsons Dis. 2011 Feb 21;2011:124165
pubmed: 21403896
Nat Rev Neurosci. 2003 Jan;4(1):13-25
pubmed: 12511858
J Pharmacol Exp Ther. 2001 Sep;298(3):1150-3
pubmed: 11504813
Subcell Biochem. 2012;65:389-455
pubmed: 23225012
Eur J Pharmacol. 2003 Jul 11;472(3):165-71
pubmed: 12871750
Physiol Rev. 2009 Apr;89(2):535-606
pubmed: 19342614
Adv Pharmacol. 2013;68:319-34
pubmed: 24054151
Physiol Rev. 1988 Jan;68(1):232-307
pubmed: 2892215
Eur J Pharmacol. 2002 Aug 2;449(1-2):71-4
pubmed: 12163108
Eur J Pharmacol. 2015 May 15;755:119-26
pubmed: 25771452
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8773-7
pubmed: 7568015
Pflugers Arch. 2004 Feb;447(5):636-40
pubmed: 12827358
J Biol Chem. 2010 Jan 15;285(3):1957-66
pubmed: 19903816
Issues Ment Health Nurs. 2022 Jan;43(1):22-31
pubmed: 34370608
J Neurochem. 1993 Dec;61(6):2314-7
pubmed: 8245983
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10993-7
pubmed: 1438304
J Pharmacol Exp Ther. 2009 Mar;328(3):807-12
pubmed: 19038779
J Biol Chem. 1962 Jul;237:2311-7
pubmed: 14456353
Neurochem Int. 2014 Jul;73:71-88
pubmed: 24704795
Handb Exp Pharmacol. 2021;266:199-214
pubmed: 33993413
Neurology. 2009 Feb 3;72(5):432-8
pubmed: 19188574
J Cereb Blood Flow Metab. 2011 Oct;31(10):2065-75
pubmed: 21522164
Expert Rev Neurother. 2006 Sep;6(9):1249-65
pubmed: 17009913
Eur J Pharmacol. 2002 Mar 1;438(1-2):75-8
pubmed: 11906713
Eur J Pharmacol. 2007 Sep 24;571(1):25-8
pubmed: 17618619
Psychiatry Investig. 2020 Nov;17(11):1073-1078
pubmed: 33099987
BMC Neurosci. 2015 Jun 19;16:35
pubmed: 26084360
Pharmacol Rev. 2004 Sep;56(3):331-49
pubmed: 15317907
Lancet Psychiatry. 2017 Aug;4(8):595-604
pubmed: 28668671
Endocr Rev. 2020 Apr 1;41(2):
pubmed: 31555796
Neuron. 1997 Dec;19(6):1285-96
pubmed: 9427251
Addict Biol. 2021 Jul;26(4):e13019
pubmed: 33538092
Exp Neurol. 1999 Mar;156(1):138-48
pubmed: 10192785
Mov Disord. 2015 Jan;30(1):45-53
pubmed: 25450307
Eur J Pharmacol. 2003 Aug 8;474(2-3):223-6
pubmed: 12921866
Ann N Y Acad Sci. 2011 Jan;1216:86-98
pubmed: 21272013
J Mol Neurosci. 1994 Fall;5(3):149-64
pubmed: 7654518
Neuroscience. 2014 Feb 14;259:194-202
pubmed: 24321511
Drug Des Devel Ther. 2018 May 14;12:1215-1238
pubmed: 29795977
AAPS J. 2005 Dec 20;7(4):E847-51
pubmed: 16594636
Expert Rev Neurother. 2014 Oct;14(10):1115-7
pubmed: 25220836
Neurochem Int. 2019 Feb;123:46-49
pubmed: 30055194
J Kidney Cancer VHL. 2017 Sep 04;4(3):30-36
pubmed: 28890865
J Hist Neurosci. 2003 Jun;12(2):207-20
pubmed: 12953623
Ann Neurol. 2010 Jun;67(6):715-25
pubmed: 20517933
Cell. 1992 Aug 21;70(4):539-51
pubmed: 1505023
Eur J Neurosci. 2017 Jan;45(1):20-33
pubmed: 27520881
Indian J Psychiatry. 2018 Feb;60(Suppl 2):S277-S283
pubmed: 29527061
J Comp Neurol. 2005 Nov 21;492(3):370-9
pubmed: 16217790
Chemosphere. 2018 Jan;191:954-961
pubmed: 29145140
Cas Lek Cesk. 2007;146(7):573-7
pubmed: 17722843
J Psychiatr Res. 2013 Nov;47(11):1760-5
pubmed: 24018103
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):474-481
pubmed: 26338179
Neuropharmacology. 2005 Nov;49(6):820-30
pubmed: 16005476
J Exp Biol. 1994 Nov;196:251-62
pubmed: 7823026
J Affect Disord. 2021 Dec 1;295:1215-1219
pubmed: 34706435
J Neurosci. 1995 Sep;15(9):6179-88
pubmed: 7666200
Curr Protoc Pharmacol. 2017 Dec 20;79:12.16.1-12.16.17
pubmed: 29261228
Ther Adv Psychopharmacol. 2019 May 20;9:2045125319847882
pubmed: 31205680
J Biol Chem. 1997 Mar 7;272(10):6752-9
pubmed: 9045708